This document describes an invention for multi-technique molecular imaging agents and their diagnostic kits. The agents can be concentrated on tumors and indicate their existence and location using techniques like MRI, PET, SPECT, and scintigraphy. The main purposes are to increase the sensitivity of imaging diagnosis and allow radiopharmaceuticals to be carried precisely to treatment sites in a less invasive way, enabling earlier diagnosis and more effective tumor treatment. The formulations are also available as "cold kits" whose procedures are already familiar to medical professionals, making them easier to adopt for diagnosis and treatment.

1. Koiti Araki, Sérgio Hiroshi Toma, Ralph Santos Oliveira
MULTI-TECHNIQUE MOLECULAR IMAGING AGENTS AND THEIR
DIAGNOSTIC KITS
Introduction
Purposes
Application and Target Markets
Development Stage
Patent protected under No.: BR 10 2017 010378-1Field: Health and Care Institute of Chemistry
This invention is especially relevant to laboratories, hospitals, public and private health
institutions that are or aim to be acknowledged as reference center in cancer treatment
and prevention.
This invention presents formulations of diagnosis nano-agents by multi-technique imaging and also their diagnosis kits based on these
formulations. Which ones are able to be concentrated on tumors and indicate their existence and localization by using techniques such as nuclear
magnetic resonance imaging, positron emission tomography (PET), PET-CT, SPECT, SPECT/CT, PET/MRI and scintigraphy. Moreover, it
eventually can be used as therapeutics agents (radiopharmaceuticals).
This invention has as main purpose to confer greater sensitivity on imaging diagnosis
techniques. In addition, it will be able to carry radiopharmaceuticals towards the precise
local of treatment in a less invasive manner; which function allows a precocious diagnosis
and more efficient tumors treatment, what increase the possibilities of healing. These
formulations are also available as ‘cold kits’, which procedure for use is already known by
medical community, what makes easier its adoption for diagnosis and treatment.
Fig. 1: bio distribution of NP combined with trastuzumab and radio-labeled
with Tc-99m in Balb-C healthy organ (above) and with induced breast
cancer (below).
0024/2016